{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T06:13:13Z","timestamp":1783750393550,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40262-026-01658-w","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T18:55:10Z","timestamp":1780599310000},"page":"1101-1112","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Model-Informed Early Prediction of Methotrexate-Induced Acute Kidney Injury in Pediatric Patients with Osteosarcoma Using Real-World Data: A Multi-center Pharmacokinetic Study"],"prefix":"10.1007","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4474-6077","authenticated-orcid":false,"given":"Patricia","family":"Rega","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3363-7262","authenticated-orcid":false,"given":"Jorge Morales","family":"Vallespin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3810-6025","authenticated-orcid":false,"given":"Azucena","family":"Aldaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Pappas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9747-4960","authenticated-orcid":false,"given":"Paulo Caceres","family":"Guido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Azocar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Villarroel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8811-1718","authenticated-orcid":false,"given":"Jennifer L.","family":"Pauley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1546-9720","authenticated-orcid":false,"given":"Clinton F.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0484-6367","authenticated-orcid":false,"given":"Manuel","family":"Ibarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2568-4731","authenticated-orcid":false,"given":"Paula","family":"Schaiquevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"1658_CR1","volume-title":"Soft tissue and bone tumour","author":"WHO Classification of Tumours Editorial Board","year":"2020","unstructured":"WHO Classification of Tumours Editorial Board. Soft tissue and bone tumour, vol. Vol. 3. 5th ed. Geneva: World Health Organization; 2020.","edition":"5th ed"},{"key":"1658_CR2","unstructured":"NCI. Osteosarcoma and UPS of bone treatment (PDQ\u00ae). https:\/\/www.cancer.gov\/types\/bone\/hp\/osteosarcoma-treatment-pdq. Accessed 4 Dec 2025."},{"issue":"6","key":"1658_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/S11912-021-01053-7","volume":"23","author":"R Belayneh","year":"2021","unstructured":"Belayneh R, Fourman MS, Bhogal S, Weiss KR. Update on osteosarcoma. Curr Oncol Rep. 2021;23(6):71. https:\/\/doi.org\/10.1007\/S11912-021-01053-7.","journal-title":"Curr Oncol Rep"},{"key":"1658_CR4","first-page":"97","volume-title":"Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975\u20132000","author":"L Mascarenhas","year":"2006","unstructured":"Mascarenhas L, Siegel S, Spector L, Arndt C, Femino D, Malogolowkin M. Malignant bone tumors. In: Bleyer A, O\u2019Leary M, Barr R, Ries L, editors. Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975\u20132000. Bethesda: National Cancer Institute; 2006. p. 97\u2013110."},{"issue":"4","key":"1658_CR5","doi-asserted-by":"publisher","DOI":"10.6004\/JNCCN.2025.0017","volume":"23","author":"JS Biermann","year":"2025","unstructured":"Biermann JS, Hirbe A, Ahlawat S, Bernthal NM, Binitie O, Boles S, et al. Bone cancer. version 2.2025, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2025;23(4):250017. https:\/\/doi.org\/10.6004\/JNCCN.2025.0017.","journal-title":"J Natl Compr Canc Netw"},{"key":"1658_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJCPED.2023.100029","volume":"2","author":"R van Ewijk","year":"2023","unstructured":"van Ewijk R, Herold N, Baecklund F, Baumhoer D, Boye K, Gaspar N, et al. European standard clinical practice recommendations for children and adolescents with primary and recurrent osteosarcoma. EJC Paediatr Oncol. 2023;2:100029. https:\/\/doi.org\/10.1016\/J.EJCPED.2023.100029.","journal-title":"EJC Paediatr Oncol"},{"issue":"3","key":"1658_CR7","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1081\/CNV-100102557","volume":"19","author":"WS Ferguson","year":"2001","unstructured":"Ferguson WS, Goorin AM. Current treatment of osteosarcoma. Cancer Invest. 2001;19(3):292\u2013315. https:\/\/doi.org\/10.1081\/CNV-100102557.","journal-title":"Cancer Invest"},{"issue":"12","key":"1658_CR8","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1634\/THEONCOLOGIST.2015-0164","volume":"21","author":"SC Howard","year":"2016","unstructured":"Howard SC, McCormick J, Pui C-H, Buddington RK, Harvey RD. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016;21(12):1471\u201382. https:\/\/doi.org\/10.1634\/THEONCOLOGIST.2015-0164.","journal-title":"Oncologist"},{"issue":"6","key":"1658_CR9","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1634\/THEONCOLOGIST.11-6-694","volume":"11","author":"BC Widemann","year":"2006","unstructured":"Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006;11(6):694\u2013703. https:\/\/doi.org\/10.1634\/THEONCOLOGIST.11-6-694.","journal-title":"Oncologist"},{"issue":"3","key":"1658_CR10","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/BF00262416","volume":"3","author":"WE Evans","year":"1979","unstructured":"Evans WE, Pratt CB, Taylor RH, Barker LF, Crom WR. Pharmacokinetic monitoring of high-dose methotrexate: early recognition of high-risk patients. Cancer Chemother Pharmacol. 1979;3(3):161\u20136. https:\/\/doi.org\/10.1007\/BF00262416.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"1658_CR11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1146\/ANNUREV-PHARMTOX-033020-113257\/CITE\/REFWORKS","volume":"61","author":"AS Darwich","year":"2021","unstructured":"Darwich AS, Polasek TM, Aronson JK, Ogungbenro K, Wright DFB, Achour B, et al. Annual review of pharmacology and toxicology: model-informed precision dosing: background, requirements, validation, implementation, and forward trajectory of individualizing drug therapy. Annu Rev Pharmacol Toxicol. 2021;61(1):225\u201345. https:\/\/doi.org\/10.1146\/ANNUREV-PHARMTOX-033020-113257\/CITE\/REFWORKS.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1658_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/J.ADDR.2024.115421","volume":"215","author":"IK Minichmayr","year":"2024","unstructured":"Minichmayr IK, Dreesen E, Centanni M, Wang Z, Hoffert Y, Friberg LE, et al. Model-informed precision dosing: state of the art and future perspectives. Adv Drug Deliv Rev. 2024;215:115421. https:\/\/doi.org\/10.1016\/J.ADDR.2024.115421.","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"1658_CR13","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/CPT.1957","volume":"108","author":"ZL Taylor","year":"2020","unstructured":"Taylor ZL, Mizuno T, Punt NC, Baskaran B, Navarro Sainz A, Shuman W, et al. MTXPK.Org: a clinical decision support tool evaluating high-dose methotrexate pharmacokinetics to inform post-infusion care and use of glucarpidase. Clin Pharmacol Ther. 2020;108(3):635\u201343. https:\/\/doi.org\/10.1002\/CPT.1957.","journal-title":"Clin Pharmacol Ther"},{"issue":"13","key":"1658_CR14","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.2165\/00003088-200241130-00006","volume":"41","author":"A Rousseau","year":"2002","unstructured":"Rousseau A, Sabot C, Delepine N, Delepine G, Debord J, Lach\u00e2tre G, et al. Bayesian estimation of methotrexate pharmacokinetic parameters and area under the curve in children and young adults with localised osteosarcoma. Clin Pharmacokinet. 2002;41(13):1095\u2013104. https:\/\/doi.org\/10.2165\/00003088-200241130-00006.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1658_CR15","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/JCPH.1349","volume":"59","author":"KH Hui","year":"2019","unstructured":"Hui KH, Chu HM, Fong PS, Cheng WTF, Lam TN. Population pharmacokinetic study and individual dose adjustments of high-dose methotrexate in Chinese pediatric patients with acute lymphoblastic leukemia or osteosarcoma. J Clin Pharmacol. 2019;59(4):566\u201377. https:\/\/doi.org\/10.1002\/JCPH.1349.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"1658_CR16","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1097\/FTD.0B013E31823615E1","volume":"33","author":"\u00c5M Johansson","year":"2011","unstructured":"Johansson \u00c5M, Hill N, Perisoglou M, Whelan J, Karlsson MO, Standing JF. A population pharmacokinetic\/pharmacodynamic model of methotrexate and mucositis scores in osteosarcoma. Ther Drug Monit. 2011;33(6):711\u20138. https:\/\/doi.org\/10.1097\/FTD.0B013E31823615E1.","journal-title":"Ther Drug Monit"},{"issue":"9","key":"1658_CR17","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1345\/APH.1A446","volume":"36","author":"I Aquerreta","year":"2002","unstructured":"Aquerreta I, Aldaz A, Gir\u00e1ldez J, Sierrases\u00famaga L, Gagnon L. Pharmacodynamics of high-dose methotrexate in pediatric patients. Ann Pharmacother. 2002;36(9):1344\u201350. https:\/\/doi.org\/10.1345\/APH.1A446.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"1658_CR18","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/PBC.10443","volume":"42","author":"I Aquerreta","year":"2004","unstructured":"Aquerreta I, Aldaz A, Gir\u00e1ldez J, Sierrases\u00famaga L. Methotrexate pharmacokinetics and survival in osteosarcoma. Pediatr Blood Cancer. 2004;42(1):52\u20138. https:\/\/doi.org\/10.1002\/PBC.10443.","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"1658_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/PHARMACEUTICS16091180","volume":"16","author":"LB Ben Olivo","year":"2024","unstructured":"Ben Olivo LB, de Oliveira Henz P, Wermann S, Dias BB, Porto GO, Pinhatti AV, et al. Anticipating leucovorin rescue therapy in patients with osteosarcoma through methotrexate population pharmacokinetic model. Pharmaceutics. 2024;16(9):1180. https:\/\/doi.org\/10.3390\/PHARMACEUTICS16091180.","journal-title":"Pharmaceutics"},{"issue":"8","key":"1658_CR20","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1002\/CNCR.20152","volume":"100","author":"KR Crews","year":"2004","unstructured":"Crews KR, Liu T, Rodriguez-Galindo C, Tan M, Meyer WH, Panetta JC, et al. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. Cancer. 2004;100(8):1724\u201333. https:\/\/doi.org\/10.1002\/CNCR.20152.","journal-title":"Cancer"},{"issue":"2","key":"1658_CR21","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1200\/JCO.2002.20.2.426","volume":"20","author":"AM Goorin","year":"2002","unstructured":"Goorin AM, Harris MB, Bernstein M, Ferguson W, Devidas M, Siegal GP, et al. Phase II\/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a Pediatric Oncology Group trial. J Clin Oncol. 2002;20(2):426\u201333. https:\/\/doi.org\/10.1200\/JCO.2002.20.2.426.","journal-title":"J Clin Oncol"},{"key":"1658_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJCPED.2023.100029","volume":"2","author":"R van Ewijk","year":"2023","unstructured":"van Ewijk R, Herold N, Baecklund F, Baumhoer D, Boye K, Gaspar N, et al. European standard clinical practice recommendations for children and adolescents with primary and recurrent osteosarcoma. EJC Paediatric Oncology. 2023;2:100029. https:\/\/doi.org\/10.1016\/J.EJCPED.2023.100029.","journal-title":"EJC Paediatric Oncology"},{"key":"1658_CR23","doi-asserted-by":"publisher","unstructured":"Kellum JA, Lameire N, Aspelin P, Barsoum RS, Burdmann EA, Goldstein SL, et al. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012. https:\/\/doi.org\/10.1038\/kisup.2012.1.","DOI":"10.1038\/kisup.2012.1"},{"key":"1658_CR24","unstructured":"R Foundation for Statistical Computing. R: a language and environment for statistical computing. https:\/\/www.R-project.org\/. Accessed 18 May 2025."},{"issue":"5","key":"1658_CR25","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1023\/A:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28(5):481\u2013504. https:\/\/doi.org\/10.1023\/A:1012299115260.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"8","key":"1658_CR26","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1056\/NEJM199802193380803","volume":"338","author":"WE Evans","year":"1998","unstructured":"Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui C-H. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med. 1998;338(8):499\u2013505. https:\/\/doi.org\/10.1056\/NEJM199802193380803.","journal-title":"N Engl J Med"},{"issue":"2","key":"1658_CR27","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/S00280-013-2206-X","volume":"72","author":"JL Pauley","year":"2013","unstructured":"Pauley JL, Panetta JC, Crews KR, Pei D, Cheng C, McCormick J, et al. Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments. Cancer Chemother Pharmacol. 2013;72(2):369\u201378. https:\/\/doi.org\/10.1007\/S00280-013-2206-X.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"1658_CR28","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1007\/S00280-006-0202-0","volume":"58","author":"DW Faltaos","year":"2006","unstructured":"Faltaos DW, Hulot JS, Urien S, Morel V, Kaloshi G, Fernandez C, et al. Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy. Cancer Chemother Pharmacol. 2006;58(5):626\u201333. https:\/\/doi.org\/10.1007\/S00280-006-0202-0.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"1658_CR29","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1248\/BPB.B13-00672","volume":"37","author":"M Watanabe","year":"2014","unstructured":"Watanabe M, Fukuoka N, Takeuchi T, Yamaguchi K, Motoki T, Tanaka H, et al. Developing population pharmacokinetic parameters for high-dose methotrexate therapy: implication of correlations among developed parameters for individual parameter estimation using the Bayesian least-squares method. Biol Pharm Bull. 2014;37(6):916\u201321. https:\/\/doi.org\/10.1248\/BPB.B13-00672.","journal-title":"Biol Pharm Bull"},{"issue":"4","key":"1658_CR30","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1080\/02841860510029770","volume":"44","author":"A Comandone","year":"2005","unstructured":"Comandone A, Passera R, Boglione A, Tagini V, Ferrari S, Cattel L. High dose methotrexate in adult patients with osteosarcoma: clinical and pharmacokinetic results. Acta Oncol. 2005;44(4):406\u201311. https:\/\/doi.org\/10.1080\/02841860510029770.","journal-title":"Acta Oncol"},{"issue":"1","key":"1658_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/S12885-021-08443-X","volume":"21","author":"U Arshad","year":"2021","unstructured":"Arshad U, Taubert M, Seeger-Nukpezah T, Ullah S, Spindeldreier KC, Jaehde U, et al. Evaluation of body-surface-area adjusted dosing of high-dose methotrexate by population pharmacokinetics in a large cohort of cancer patients. BMC Cancer. 2021;21(1):719. https:\/\/doi.org\/10.1186\/S12885-021-08443-X.","journal-title":"BMC Cancer"},{"issue":"3","key":"1658_CR32","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/CAD.0B013E3282F21376","volume":"19","author":"C Dupuis","year":"2008","unstructured":"Dupuis C, Mercier C, Yang C, Monjanel-Mouterde S, Ciccolini J, Fanciullino R, et al. High-dose methotrexate in adults with osteosarcoma: a population pharmacokinetics study and validation of a new limited sampling strategy. Anticancer Drugs. 2008;19(3):267\u201373. https:\/\/doi.org\/10.1097\/CAD.0B013E3282F21376.","journal-title":"Anticancer Drugs"},{"issue":"2","key":"1658_CR33","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/BCP.15506","volume":"89","author":"M Ibarra","year":"2023","unstructured":"Ibarra M, Combs R, Taylor ZL, Ramsey LB, Mikkelsen T, Buddington RK, et al. Insights from a pharmacometric analysis of HDMTX in adults with cancer: clinically relevant covariates for application in precision dosing. Br J Clin Pharmacol. 2023;89(2):660\u201371. https:\/\/doi.org\/10.1111\/BCP.15506.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1658_CR34","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/J.1365-2125.2005.02513.X","volume":"62","author":"M Joerger","year":"2006","unstructured":"Joerger M, Huitema ADR, Van Den Bongard HJGD, Baas P, Schornagel JH, Schellens JHM, et al. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. Br J Clin Pharmacol. 2006;62(1):71\u201380. https:\/\/doi.org\/10.1111\/J.1365-2125.2005.02513.X.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1658_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/PBC.27618","volume":"66","author":"LB Ramsey","year":"2019","unstructured":"Ramsey LB, Mizuno T, Vinks AA, O\u2019Brien MM. Delayed methotrexate clearance in patients with acute lymphoblastic leukemia concurrently receiving dasatinib. Pediatr Blood Cancer. 2019;66(5):e27618. https:\/\/doi.org\/10.1002\/PBC.27618.","journal-title":"Pediatr Blood Cancer"},{"issue":"35","key":"1658_CR36","doi-asserted-by":"publisher","first-page":"5972","DOI":"10.1200\/JCO.2008.20.4156.","volume":"27","author":"LR Trevi\u00f1o","year":"2009","unstructured":"Trevi\u00f1o LR, Shimasaki N, Yang W, Panetta JC, Cheng C, Pei D, et al. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol. 2009;27(35):5972\u20138. https:\/\/doi.org\/10.1200\/JCO.2008.20.4156.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1658_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS13112837","volume":"13","author":"ZL Taylor","year":"2021","unstructured":"Taylor ZL, Vang J, Lopez-Lopez E, Oosterom N, Mikkelsen T, Ramsey LB. Systematic review of pharmacogenetic factors that influence high-dose methotrexate pharmacokinetics in pediatric malignancies. Cancers (Basel). 2021;13(11):2837. https:\/\/doi.org\/10.3390\/CANCERS13112837.","journal-title":"Cancers (Basel)"},{"issue":"11","key":"1658_CR38","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1080\/10428194.2020.1783445","volume":"61","author":"D Mullikin","year":"2020","unstructured":"Mullikin D, Ranch D, Khalfe Y, Lucari B, Zobeck MC, Assanasen C, et al. Hispanic ethnicity is associated with prolonged clearance of high dose methotrexate and severe nephrotoxicity in children and adolescents with acute lymphoblastic leukemia. Leuk Lymphoma. 2020;61(11):2771\u20134. https:\/\/doi.org\/10.1080\/10428194.2020.1783445.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"1658_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/J.IJANTIMICAG.2024.107332","volume":"64","author":"J Chang","year":"2024","unstructured":"Chang J, Pais GM, Barreto EF, Young B, Scott H, Schwartz Z, et al. Past, present, and future biomarkers of kidney function and injury: the relationship with antibiotics. Int J Antimicrob Agents. 2024;64(5):107332. https:\/\/doi.org\/10.1016\/J.IJANTIMICAG.2024.107332.","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"1658_CR40","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s40262-026-01618-4","volume":"65","author":"ZL Taylor","year":"2026","unstructured":"Taylor ZL, Barreto EF, Cole KC, Rule AD, Kashani KB, Leung N, et al. Use of a cystatin C-based GFR equation in a population pharmacokinetic model of methotrexate clearance in adult patients with lymphoma. Clin Pharmacokinet. 2026;65(3):465\u201377. https:\/\/doi.org\/10.1007\/s40262-026-01618-4.","journal-title":"Clin Pharmacokinet"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01658-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01658-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01658-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T05:36:52Z","timestamp":1783748212000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01658-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1658"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01658-w","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"2 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patricia Rega, Jorge Morales Vallespin, Azucena Aldaz, Andrew Pappas, Paulo Caceres Guido, Manuel Azocar, Milena Villarroel, Jennifer L. Pauley, Clinton F. Stewart, Manuel Ibarra, and Paula Schaiquevich have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"Ethical approval was obtained from the institutional review boards of all participating institutions: Hospital de Pediatr\u00eda Prof. Dr. Juan P. Garrahan (Protocol No. 603), Hospital Dr. Luis Calvo Mackenna (Protocol No. GLATO-2015), and St. Jude Children\u2019s Research Hospital (Protocol Nos. 23-1285 and OS08).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants, parents, and\/or legal representatives provided informed consent according to the protocols that were approved by the institutional review board of each participating institution.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that human research participants, parents, or legal representatives provided informed consent for publication of their data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets that support the findings of this study are not publicly available because of institutional privacy policies but may be made available from the corresponding author upon reasonable request and with appropriate data use agreements.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"No custom code was developed for the study analysis beyond standard model scripts used in MonolixSuite\n                      \u00ae\n                      2024R1 (Lixoft SAS; Simulations Plus, Antony, France).","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conception and design: JMV, AA, CFS, MI, PS. Data collection and curation: PR, JMV, AA, AP, PCG, JLP, CFS. Patient management: MV, JLP. Data analysis: PR, MI, PS. All authors contributed to the drafting and critical revision of the manuscript, and read and approved the final version of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}